biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Causing Implausible Speculation, With No Responsibilty

<< Previous

Bullboard Posts

Next >>

Comment by zwerp2000on Feb 22, 2023 9:16pm

55 Views

Post# 35299831

RE:RE:RE:RE:RE:RE:RE:Causing Implausible Speculation, With No Responsibilty

because the xb3 platform is junk. there's a reason no big company has stepped up to do anything with it and why the company can't raise money and is about to go bankrupt. those that tell you xb3 has value and there is some sort of conspiracy to screw shareholders either have ulterior motives or are just foolish and naive

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading